Use access key #2 to skip to page content.

quinpeung (76.84)

October 2010



Finding studies on reboxetine: a tale of hide and seek

October 13, 2010 – Comments (0)

All so quick to bash the FDA regarding new drug approvals might want to consider the case of reboxetine.  A report in the October 12th issue of the British Medical Journal details how Pfizer selectively published trial results that led to the approval of the drug in Europe.  As background, the antidepressant reboxetine, a selective noradrenaline (norepinephrine) reuptake inhibitor, was approved in several European countries (including the United Kingdom and Germany) in 1997. However, approval was declined in the United States in 2001. The German Institute for Quality and Efficiency in Health Care report on the benefit and harm of newer antidepressants concluded in 2009 that, overall, reboxetine was both ineffective and potentially harmful.  [more]

Featured Broker Partners